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Background: The biological activity of many microbial products requires the
presence of one or more deoxysugar molecules attached to agylcone. This is
especially prevalent among polyketides and is an important reason that the
antitumor anthracycline antibiotics are avid DNA-binding drugs. The ability to
make different deoxyaminosugars and attach them to the same or different
aglycones in vivo would facilitate the synthesis of new anthracyclines and the
quest for antitumor drugs. This is feasible using the numerous bacterial genes
for deoxysugar biosynthesis that are now available.
Results: Production of thymidine diphospho (TDP)-L-daunosamine (dnm), the
aminodeoxysugar present in the anthracycline antitumor drugs daunorubicin
(DNR) and doxorubicin (DXR), and its attachment to ε-rhodomycinone to
generate rhodomycin D has been achieved by bioconversion with a strain of
Streptomyces lividans that bears two plasmids. One contained the
Streptomyces peucetius dnmJVUZTQS genes plus dnmW (previously named
dpsH and considered to be a polyketide cyclase gene), dnrH, which is not
required for the formation of rhodomycin D, and dnrI, a regulatory gene required
for expression of the dnm and drr genes. The other plasmid had genes
encoding glucose-1-phosphate thymidylyltransferase and TDP-glucose-
4,6-dehydratase (dnmL and dnmM, respectively, or mtmDE, their homologs
from Streptomyces agrillaceus) plus the drrAB DNR/DXR resistance genes.
Conclusions: The high-yielding glycosylation of the aromatic polyketide
ε-rhodomycinone using plasmid-borne deoxysugar biosynthesis genes proves
that the minimal information for L-daunosamine biosynthesis and attachment in
the heterologous host is encoded by the dnmLMJVUTS genes. This is a
general approach to making both known and new glycosides of anthracyclines,
several of which have medically important antitumor activity.
Introduction
The biosynthesis of daunorubicin (DNR) and doxorubicin
(DXR), two anthracyclines produced by Streptomyces peucetius
ATCC 29050 [1–3] that have potent antitumor activity [4,5],
takes place in two stages (Figure 1). A biologically inactive,
polyketide-derived aglycone, ε-rhodomycinone (RHO),
is formed first, then the 2,3,6-trideoxy-3-aminohexose,
L-daunosamine, is attached to give rhodomycin D (RHOD).
DNR and DXR result by further metabolism of RHOD and,
as with many microbial secondary metabolites, require a
deoxyhexose component for their biological activity [6].
The daunosamine biosynthesis genes (Figure 1, inset) have
been cloned and sequenced in previous work (reviewed in
[7,8]). Nine genes are believed to be involved; dnmJ, dnmL,
dnmM, dnmV, dnmU, dnmZ, dnmT, dnmQ, and dnmS (many
of these were named ‘dnr’ formerly). Their proven or pos-
tulated functions are given in Table 1 along with selected
homologs from the desosamine, mycarose or oleandrose
pathways in other bacteria ([9–16], reviewed in 17–19]).
The putative glucose-1-phosphate thymidylyltransferase
gene dnmL, which presumably governs the first step of
daunosamine biosynthesis, is adjacent to dnmM, which
encodes an apparently nonfunctional thymidine diphospho
(TDP)-glucose-4,6-dehydratase resulting from a frameshift
mutation in the open reading frame [20]. Interestingly, the
gene encoding the functional TDP-glucose-4,6-dehy-
dratase isolated from S. peucetius and the closely related
Streptomyces sp. strain C5 [21] lies somewhere outside the
DXR cluster [20]. Although the functions of dnmT [22] and
dnmQ [23] are unknown, recent work on two dnmT
homologs for granaticin biosynthesis in Streptomyces violoce-
oruber Tü22 (gra-ORF27) and oleandomycin biosynthesis in
Streptomyces antibioticus Tü99 (Tü99-ORF10) has shown that
such genes are involved in C2-deoxygenation [24]. C2-
deoxygenation might involve two or three proteins [17–19],
and in the case of the daunosamine pathway, DnmQ and
DnmZ have been proposed to participate in this step along
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with DnmT [23,25]. The dnmS gene should encode the
glycosyltransferase for the DNR pathway [23]. Another
putative glycosyltransferase gene, dnrH [22] might govern
the addition of a second daunosamine [5] or some other
carbohydrate-derived moiety to C4′ of DNR. The func-
tion of many of these genes has been predicted from the
results of gene disruption or replacement experiments
that led to the accumulation of RHO, the last intermediate
in the biosynthesis of DNR and DXR that lacks a sugar
moiety (Figure 1). These postulates also depend upon the
roles played by the dnm homologs in the biosynthesis of
other deoxyhexoses (see Table 1). DnmV and the prod-
ucts of the avrE and eryBIV genes, however, have been
proven to be TDP-4-ketohexulose reductases through the
synthesis of 4′-epimeric anthracyclines derived from DNR
and DXR [26].
To learn whether the dnm genes identified previously
are the only ones necessary for glycosylation, we
attempted to bioconvert RHO to RHOD by introduction
of the dnm genes into the heterologous host Streptomyces
lividans. These genes were cloned together with the dnrI
regulatory gene [27] for the transcription factor that is
required for expression of the DNR and DXR biosynthe-
sis and resistance genes [28–30]. Although S. lividans
contains a dnrI homolog (actII-ORF4), this gene appears
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Proposed pathway for daunosamine biosynthesis (inset) and attachment to RHO in the biosynthesis of DNR and DXR. The sequence of steps in
the daunosamine pathway beyond the formation of TDP-4-keto-6-deoxyglucose is unknown.
to be poorly expressed and we felt that it might not sub-
stitute for dnrI. The drrAB DNR and DXR resistance
genes [31] were also included to give S. lividans adequate
resistance to RHOD. Finally, to augment the natural
activities of glucose-1-phosphate thymidylyltransferase
and TDP-glucose-4,6-dehydratase present in S. lividans,
we used either the Streptomyces argillaceus mtmD and
mtmE genes [32], homologs of dnmL and dnmM that are
involved in the biosynthesis of mithramycin, or dnmL
and a version of dnmM in which the frameshift mutation
had been repaired.
The gene cloning and expression experiments were also
designed to re-examine the role of the dpsH gene in the
biosynthesis of TDP-daunosamine and RHOD. This gene
was initially thought to encode a type of polyketide
cyclase [33] but further investigation has led recently to a
different hypothesis, that dpsH is involved either in the
biosynthesis of TDP-daunosamine or its attachment to
RHO [34]. Because of these contradictory results, we pre-
pared an in-frame dpsH mutation in the S. peucetius chro-
mosome and compared its properties with those of the
plasmid-borne daunosamine gene cassettes with and
without dpsH. As a result we renamed this gene dnmW,
reflecting its importance in the glycosylation of RHO.
Results
Re-evaluation of the role of the dpsH (dnmW ) gene
In earlier work we made a S. peucetius dpsH::aphII mutant,
the WMH1666 strain, to assess the importance of dpsH for
DNR and DXR production [34]. Given that the WMH1666
strain accumulated a considerable amount of RHO but no
DNR or DXR, dpsH cannot be a polyketide cyclase.
The dpsH::aphII mutation was complemented only by
introducing the dspH, dnmT and dnrH genes together,
which indicated that the dpsH::aphII mutation must have a
polar effect on expression of the dnmT and dnrH genes [34].
This complicated interpretation of the results and made it
difficult to clearly assign a role to the dpsH gene. Conse-
quently, to avoid this problem, we constructed a 284 base-
pair in-frame deletion between the NcoI and HincII sites in
dpsH by gene replacement (see Table S1 in the Supple-
mentary material). The resulting 1.7 kb KpnI–BalI fragment
containing the in-frame deletion was cloned into the phage-
derived KC515 vector as phWHM456 and this phage con-
struct was used to replace the wild-type dpsH gene with its
in-frame mutant [34]. Three representative mutant strains,
WMH1803, WMH1804 and WMH1805, with the correct
genotype (data not shown) were grown under standard con-
ditions for DNR and DXR production. Thin layer chro-
matography (TCL) analysis of the culture extracts showed
that all of these strains accumulated considerable amounts
of RHO but still produced DNR and DXR. By high-perfor-
mance liquid chromatography (HPLC) analysis they were
found to produce 160–273%, 23–34% and 10–24% of the
amounts of RHO, DNR and DXR, respectively, that were
produced by the S. peucetius 29050 wild-type strain used as a
control. These data confirm that dpsH, now renamed dnmW,
has an important but not absolutely essential role in the for-
mation of the anthracycline glycosides RHOD, DNR and
DXR. Because glycosylation was not entirely abolished, we
speculate that the in-frame dnmW mutation was partially
suppressed by another locus in S. peucetius or that the step in
which the DnmW enzyme participates can proceed sponta-
neously to a small extent. This issue will have to be revis-
ited through studies of purified DnmW in due course.
Construction and evaluation of the repaired dnmM gene
So that we could use all of the dnm genes in the bioconver-
sion experiments, the frameshift in the wild-type dnmM
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Table 1
The TDP-L-daunosamine biosynthesis and glycosyltransferase genes and homologs.
Gene* Function† Homolog(s)
dnmL Glucose-1-phosphate thymidylyltransferase [20] mtmD [32], avrD [16], desIII [15]
dnmM TDP-glucose-4,6-dehydratase ([20]; this study) mtmE [32], avrC [16], desIV [15]
dnmJ C3-aminotransferase [28] eryCI [9–12], eryCIV [9–12], desV [15] oleN2 [14]
dnmZ Unknown; putative flavoprotein ([25]; this study) None in deoxysugar pathways
dnmU Putative TDP-4-keto-6-deoxyglucose-3(5)-epimerase [25] eryBVII [9–12], avrF [16]
dnmV TDP-4-ketohexulose reductase [25] eryBIV [9–12], avrE [16]
dnmW Unknown ([34]; this study) actVI-ORFA [33], mtmX [33], frenX [33]
dnmT Putative TDP-4-keto-6-deoxy-2,3-dehydrase [22] eryBVI [9–12], avrG [16], gra-ORF27 [24], Tü99-ORF10 [24]
dnmQ Unknown [23] eryCII [9–12], desVIII [16], oleP1 [13]
dnmS Putative TDP-L-daunosaminyl transferase [23] eryCIII [9–12], eryBV [9–12], desVII [15], oleG1 [13,14], 
oleG2 [13,14], avrB [16]
*The genes are listed in the order that they occur in the DNR/DXR gene cluster. †As proposed in the cited reference(s). 
open reading frame was repaired (see the Materials and
methods section). The resulting dnmM+ gene was intro-
duced by gene replacement into an S. peucetius dnmM::aphII
mutant (WMH1800) made from the wild-type ATCC
29050 strain (see the Materials and methods section) to
give S. peucetius WMH1801 and WMH1802 strains contain-
ing the dnmM+ gene. These two strains, the WMH1800
dnmM::aphII strain and the S. peucetius 29050 strain were
grown under standard conditions for anthracycline produc-
tion, and the culture extracts were analysed by HPLC. The
resulting data showed that the WMH1800 strain produced
lower amounts of DNR (40%) and DXR (52%) in compari-
son with the amounts produced by the 29050 control strain
(Table 2). As noted previously, therefore, the dnmM::aphII
mutation was suppressed by another S. peucetius locus that
produces functional TDP-glucose-4,6-dehydratase. The
WMH1801 and WMH1802 dnmM+ strains produced almost
the same amounts of DNR (118% and 113%, respectively)
as the 29050 control strain, but the amounts of DXR were
increased 1.6 to 1.8 times over  the control strain (Table 2).
The WMH1800 strain produced lower amounts of RHO
(57%) in comparison with the 29050 control strain, whereas
the WMH1801 and WMH1802 strains produced almost the
same amount (95% and 116%, respectively) as the control. 
Although these data confirm our earlier suggestion that a
better yield of DNR or DXR might be obtained after
restoring the frameshift in the wild-type dnmM gene, we
cannot rationalize the fact that the dnmM::aphII mutant
produced less RHO, DNR and DXR than the 29050
strain. It is clear, however, from the bioconversion experi-
ments described below that the dnmM+ gene functions in
S. lividans as expected.
Construction of the daunosamine gene cassettes
Following completion of the above work, our cloning 
strategy for the daunosamine genes took two things into 
consideration. Instead of attempting to clone the dnm
genes in one orientation downstream of an artificial pro-
moter, which is complicated by the fact that these genes
are located in four different regions of the DXR gene
cluster [7,8], their natural arrangement and native promot-
ers were used as far as possible. This simplified the
cloning work and also allowed enhanced expression of the
dnm genes by increasing the amount of the positively
acting dnrI gene. Two plasmid vectors instead of one were
used, again for simplification because DnrI can act in trans
on the dnm promoters in both plasmids. The mtmD and
mtmE or dnmL and dnmM+ genes were cloned on the low
copy pWHM601 vector [31] under control of the dnrF pro-
moter, as pWHM1912 and pWHM1915, respectively
(Figure 2a). The other dnm genes were cloned on the high
copy pWHM3 vector [35] in three different arrangements
(Figure 2b). The dnrI/dnmJ and dnmZ/dnmU/dnmV genes
have the same (native) arrangement in all three plasmids.
In pWHM1906 the dnmT, dnmQ and dnmS genes were
cloned downstream of the dpsY promoter (dpsY is a
polyketide cyclase gene and is followed by dnrX of which
the exact function is unknown [36]). In pWHM1909, the
dnmW, dnmT, dnrH, dnmQ and dnmS genes were cloned
downstream of the dnmW promoter. In pWHM1910, the
dnmW, dnmT and dnrH genes were cloned under control of
the dnmW promoter, and the dnmQ and dnmS genes under
control of the divergently oriented dpsG promoter (dpsG is
a polyketide synthase gene [34]).
Plasmids in which one of the dnm genes was deleted were
also constructed and evaluated by bioconversion experi-
ments to determine the minimal number of genes required.
In each of the following plasmids the dnm gene specified in
parenthesis was deleted so as not to affect expression of the
remaining genes: pWHM1916 (dnmZ), pWHM1919 (dnrH),
pWHM1921 (dnmW) and pWHM1924 (dnmQ). The experi-
mental details for all of the above constructions are given in
the Materials and methods section and in the Supplemen-
tary material (Figure S1; Tables S1 and S2).
Complementation experiments to verify functions of dnm
genes
Before introducing the dnm gene cassettes into S. lividans,
we verified that each dnm gene was functional by carrying
out complementation experiments with S. peucetius
mutant strains that accumulate RHO and do not produce
DNR. The pWHM1906, pWHM1909 or pWHM1910
(Figure 2;  Table S1) was introduced into the S. peucetius
WMH1425 (dnrI::aphII), WMH1524 (∆dnmJ), WMH1621
(dnmV::aphII), WMH1628 (dnmQ::aphII), WMH1629
(dnmZ::aphII), WMH1673 (dnmU::aphII), WMH1713
(dnmT::aphII), WMH1666 (dnmW::aphII) strains (Table S1),
and the S. peucetius var. caesius H6125 dnmS mutant
[37,38]). These mutations were complemented when the
plasmid was introduced by transformation and the
recombinant strains were grown in APM medium [31,34]
(Table 3). In most cases, approximately the same amount
of DNR was produced by the recombinant strains as by
the wild-type control strain. When strains H6125 and
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Table 2
Anthracycline titers of S. peucetius 29050, WMH1800,
WMH1801 and WMH1802 strains.
Titers (µg/ml)*
Strains DNR DXR
29050 4.0 ± 0.5 4.6 ± 0.5
WMH1800 dnmM::aphII 1.6 ± 0.4 2.4 ± 0.2
WMH1801 dnmM+ 4.7 ± 0.6 8.4 ± 1.5
WMH1802 dnmM+ 4.5 ± 0.4 7.2 ± 0.5
*The cultures were grown in APM medium for 120 h and worked up as
described in the Materials and methods section. Data are averaged
with standard errors obtained from three independent fermentations.
WMH1713 carried pWHM1906, however, a lower amount
of DNR was produced compared with the wild-type
strain. No complementation or very low amounts of DNR
production were observed when strain WMH1628 carried
pWHM1906. We assume that the latter results stem from
use of the dpsY promoter in pWHM1906 to express the
dnmT, dnmQ and dnmS genes, or to instability of the
mRNA produced from the artificial dnmTQS operon. This
rationalization is supported by the fact that dnmT in its
native operon (dnmW/dnmT/dnrH) and dnmQS were fully
functional in pWHM1909 and pWHM1910, neither of
which employ the dpsY promoter. In addition, the dnmQS
genes also complemented the dnmQ::aphII mutation in the
WMH1628 strain when cloned under the control of the
ermE*p promoter [39] as pWHM1902 (Table 3).
Complementation of the mutations in strains WMH1629
(dnmZ::aphII) and WMH1628 (dnmQ::aphII) was also
achieved (Table 3) by introduction of plasmids pWHM1916
(∆dnmZ) and pWHM1924 (∆dnmQ) (Table 3). In the
WMH1629/pWHM1916 recombinant, the levels of RHO,
DNR and DXR produced were close to those obtained
with the wild-type strain, but in the WMH1628/pWHM1924
strain considerably less DNR and DXR were produced.
(The latter result is consistent with the behavior of
pWHM1924 in bioconversion experiments described
below.) Neither dnmZ nor dnmQ are strictly essential,
therefore, for the biosynthesis of the anthracycline glyco-
sides produced by S. peucetius.
Bioconversion of RHO to RHOD in S. lividans
Bioconversion experiments using S. lividans strains carrying
the dnm gene constructs cloned in pWHM1906, pWHM1909
or pWHM1910, each together with pWHM1912, were ini-
tially performed in four different liquid growth media:
R2YE [40], TSB, APM [31,34], or the SMM330 modifica-
tion of the SMM medium [41]. Seed cultures were pre-
pared by growing a strain for three to four days in R2YE or
APM then transferring it to fresh medium containing
RHO, after which the cultures were incubated for three
additional days before the bioconversion products were
extracted by a solvent. Less than 1% bioconversion was
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Structure of plasmid-borne daunosamine gene clusters used for
biotransformations. (a) pWHM1912 and pWHM1915 cloned in
pWHM601. (b) pWHM1906, pWHM1909 and pWHM1910 cloned in
pWHM3. Filled wedges oriented in the direction of expression indicate
the genes, open brackets indicate partial ORFs, and open black circles
indicate the promoter regions of the designated genes. Restriction site
abbreviations: A, AflII; B, BamHI; Bg, BglII; E, EcoRI; Ev, EcoRV; H,
HindIII; Su, StuI; Sy, StyI; [ ] indicates that the site was blunt-ended.
observed using the S. lividans WMH1909 (with pWHM1909
and pWHM1912) and WMH1911 (with pWHM1910 and
pWHM1912) strains, and no bioconversion with strains
WMH1906 (with pWHM1906 and pWHM611), WMH1908
(with pWHM1980 and pWHM611) and WMH1910 (with
pWHM1910 and pWHM611) (Table S2). The results from
the latter three strains were as expected because the mtmD
and mtmE genes were not included in the plasmids intro-
duced (pWHM611 contains only the drrAB resistance
genes). When these experiments were repeated after com-
pletion of the work with the solid growth medium, however,
greater than 85% bioconversion of RHO to RHOD was
obtained with the S. lividans WMH1911 strain grown in
R2YE for seven days but less than 2% when it was grown in
APM for the same period. 
To check the stability of RHOD under these conditions,
10 µg/ml of it was incubated in the R2YE, APM or
SMM330 media for three days, and the culture was
worked up under acidic conditions and extracted with
chloroform. RHOD was found to be degraded up to 50%
because of the oxalic acid treatment, following the proce-
dure of Otten et al. [42]; in the absence of the acid treat-
ment, RHOD was stable in R2YE but not in APM (in this
case the SMM330 medium was not tested).
We also performed the bioconversion experiments using
solid growth media. When strains WMH1910 (without
the mtmD and mtmE genes) and WMH1911 (with
pWHM1910 and pWHM1912) were grown in APM solid
medium containing 10 µg/ml RHO at 30°C for seven days
until well sporulated, we observed ~20% RHO bioconver-
sion with WMH1911 and less than 0.7% bioconversion for
the WMH1910 strain. The low bioconversion in the latter
case presumably reflects the level of endogenous glucose-
1-phosphate thymidylyltransferase and TDP-glucose-4,6-
dehydratase activity in S. lividans. Using solid TSB,
R2YE, SSM330 or APM media, strains WMH1906 (without
the mtmD and mtmE genes) and WMH1907 (with the
dpsY promoter driving expression of dnmTQS) were
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Table 3
S. peucetius mutant strains and complementation by different plasmid-borne daunosamine biosynthetic genes.
Strain Genotype* Plasmid Phenotype
WMH1425 dnrI::aphII, dnmJ –† –‡
pWHM1906 DNR/DXR§
WMH1524 ∆dnmJ – RHO
pWHM1906 DNR/DXR
WMH1621 dnmV::aphII – RHO
pWHM1906 DNR/DXR
WMH1628 dnmQ::aphII, dnmS – RHO
pWHM1906 RHO
pWHM1909 DNR/DXR
pWHM1910 DNR/DXR
pWHM1902¶ DNR/DXR
pWHM1924# DNR/DXR**
WMH1629 dnmZ::aphII, dnmU, dnmZ – RHO
pWHM1906 DNR/DXR
pWHM1916†† DNR/DXR
WMH1673 dnmU::aphII – RHO
pWHM1906 DNR/DXR
WMH1713 dnmT::aphII – RHO
pWHM1906 DNR/DXR**
pWHM1909 DNR/DXR
pWHM1910 DNR/DXR
WMH1666 dnmW::aphII, dnmT, dnrH – RHO
pWHM1909 DNR/DXR
pWHM1910 DNR/DXR
H6125 dnmS – RHO
pWHM1906 DNR/DXR**
*The mutant or nonfunctional genes are indicated. †No plasmid was
introduced; all plasmids are shown in Figure 2. ‡No anthracycline
metabolites were produced. §Produced at the same level as seen in
the wild-type strain. ¶pWHM1902 (Table 2) was modified to express
the dnmQ and dnmS genes under control of the ermE*p promoter.
#Same as pWHM1910 (Figure 2) but with in-frame deletion in dnmQ.
**Produced at a lower level than seen in the wild-type strain. ††Same as
pWHM1910 (Figure 2) but with an in-frame deletion in dnmZ.
unable to bioconvert RHO to RHOD. Successful biocon-
version was observed with strains WMH1909 (with
pWHM1909 and pWHM1912) grown in R2YE and TSB,
and with WMH1911 grown in R2YE, APM, TSB or
SMM330. R2YE was the best growth medium (95% bio-
conversion by WMH1911) followed by APM, TSB and
SMM330. No degradation of RHOD was observed under
these conditions.
Bioconversion of RHO by strain WMH1912 carrying dnmL
and the dnmM+ gene, instead of mtmD and mtmE as in
strain WHM1911, was analysed in R2YE and showed
lower levels of bioconversion than strain WHM1911 (46%
of the amount observed with the latter strain). The reason
for the apparently lower efficiency of the dnmL and
dnmM+ genes is not known but is less likely to be because
of differences in expression than because of differences in
the intrinsic activity of the two sets of enzymes.
Bioconversion by S. lividans strains carrying plasmids with
deletions in specific dnm genes — WMH1913/∆dnmZ,
WMH1914/∆dnrH, WMH1915/∆dnmW and WMH1916-
/∆dnmQ — were performed in R2YE solid medium. In
these experiments RHO was bioconverted to RHOD at
90%, 95%, 7% and 29% relative efficiency, respectively,
compared with the bioconversion obtained with strain
WMH1911 carrying the entire set of dnm genes. Similar
results were obtained with plasmids bearing combina-
tions of three of these single mutations: ∆dnmZ/∆dnmQ
(15%); ∆dnmZ/∆dnrH (93%); ∆dnmQ/∆dnrH (7%) and
∆dnmZ/∆dnmQ/∆dnrH (3%). These results confirm our
conclusions about the roles of the dnmZ, dnrH, dnmW and
dnmQ genes stated above; dnmZ and dnrH are dispensi-
ble whereas dnmW and dnmQ are not absolutely essential
in the heterologous host S. lividans.
Discussion
Efforts to produce new drugs by combinatorial biosynthesis
and related microbiological methods have been described
with increasing frequency during the past few years. To
date, these have largely involved engineered polyketide
synthase (e.g., [43–48]) or nonribosomal peptide synthase
([49,50]) genes, or the introduction of a deoxysugar biosyn-
thetic gene into different hosts (e.g., [51–53]). 
A parallel combinatorial approach involving engineered
deoxysugar biosynthesis genes is feasible given that con-
siderable information about these pathways is now avail-
able [17–19,54]. In fact, a few new macrolides that
are closely related to the erythromycin and methy-
mycin/picromycin antibiotics have been produced recently
by strains with targeted mutations in such genes
[11,12,55,56]. We were not able to make DNR and DXR
analogs using this approach because of the small amounts
produced by the S. peucetius dnm mutants. Moreover,
because the construction of strains with chromosomal
mutations is inherently time-consuming, a more efficient
method for combinatorial biosynthesis with deoxysugar
biosynthesis genes is required to fully exploit its potential.
McDaniel et al. [47] have illustrated clearly the power of
plasmid-borne genes in the context of combinatorial
biosynthesis and this motivated our studies.
The results of the bioconversion experiments with an
anthracycline aglycone confirm the role we had assigned
to the dnm genes in earlier work, although we still cannot
predict the exact function of the DnmW protein. Interest-
ingly, they also demonstrate that the dnmQ, dnmW and
dnmZ genes are not absolutely essential in the heterolo-
gous host, although the lack of either dnmQ or dnmW
severely reduces the formation of TDP-daunosamine.
Whether or not this means that S. lividans contains
enzymes that function very much like DnmZ, DnmW and
DnmQ or that TDP-daunosamine biosynthesis can take
place to some extent in their absence awaits studies using
the purified enzymes.
Of more interest is our demonstration that artificial
operons containing several deoxysugar biosynthesis genes
can be constructed on plasmid vectors and can function in
alternative regions of the genome as well as in their
native arrangement. Two or more vectors, including epi-
somic and integrated forms, could be used as along as the
genes are expressed at a similar level. The same approach
should be useful with erythromycin where the genes gov-
erning mycarose and desosamine biosynthesis also are
scattered throughout the erythromycin gene cluster. In
fact, we have recently been able to make new daunoru-
bicin, erythromycin and avermectin analogs using the
dnm and eryC genes through the approach illustrated here
(K. Kulowski, C. Olano, S.-E. Wohlert and C.R.H.,
unpublished observations). Consequently, we anticipate
that this combinatorial biosynthesis technique will be
broadly applicable.
Significance
Expression of the thymidine diphospho (TDP)-
daunosamine biosynthesis and glycosyltransferase genes
in Streptomyces lividans to obtain an efficient conversion
of ε-rhodoncycinone (RHO) to rhodomycin D (RHOD)
sets the stage for using these as well as other types of
deoxysugar biosynthesis genes in combinatorial biosyn-
thesis studies. Structure/function surveys of deoxysugar
biosynthesis enzymes can be done much more rapidly
with plasmid-borne genes in vivo than with their chro-
mosomal counterparts or with the purified enzymes
themselves. In this way, the inherent flexibility of the
enzymes towards normal and unusual substrates can be
assessed expediently, especially for the glycosyltrans-
ferases such as DnmS that are the gate-keepers for gly-
cosylation. The approach described should be useful for
making glycosides of other types of microbial products
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and will facilitate attempts to make new drugs by combi-
natorial biosynthesis.
Materials and methods
Bacterial strains and plasmids
S. peucetius var. caesius H6125 [37,38] was obtained from Ho Coy-
Choke (University of Malaya). S. peucetius ATCC 29050 mutants used
in this work are listed in Table 2. S. lividans 1326 [57] was obtained
from David Hopwood (John Innes Institute). E. coli strain DH5α [58] and
plasmids pUC19 [59], pSE380 (Invitrogen), pGEM7Zf(–) (Promega)
and Litmus 28 (New England Biolabs) were used for routine subcloning.
High-copy-number Streptomyces shuttle vector pWHM3 [35] and low-
copy-number shuttle vector pWHM601 [31] were from our laboratory.
pFLADE [32] used as a source of the mtmD and mtmE genes was pro-
vided by José A. Salas (University of Oviedo). Other Streptomyces
strains, plasmids and φC31-derived phages used or generated in this
study are listed in Table S1.
Media, growth conditions and fermentations
S. lividans strains were maintained on R2YE agar [40] and grown in
R2YE liquid medium for preparation of protoplasts and seed inoculum
for fermentations. Seed inoculum was also grown in APM media
[31,34]. Bioconversion experiments were performed using TSB (BRL
Microbiology Systems, Cockeysville, MD), R2YE [40], SMM330 minimal
medium containing 330 mM glucose instead of 55 mM as in the origi-
nal SMM medium [41], and APM media all supplemented with RHO
(Pharmacia & Upjohn, Italy) at 10 mg/ml. Analysis of DNR resistance
was performed as described in [31] by plating spores of S. lividans on
TSB agar containing 5, 10 and 15 µg/ml DNR. Cultures for preparation
of S. peucetius spores were grown on ISP4 solid medium (Difco Labo-
ratories, Detroit, MI). APM seed and production media were used to
determine anthracycline production in S. peucetius. Streptomyces pro-
toplasts were regenerated on R2YE agar. Streptomyces plasmids were
selected with thiostrepton (obtained from S.L. Lucania, Bristol-Myers-
Squibb, Princeton, NJ) at 50 µg/ml in solid medium and 5 µg/ml in
liquid medium, or apramycin (Fluka Chemical Co.) at 25 mg/ml. S.
peucetius mutants containing the resistance gene aphII were selected
with kanamycin at 20 µg/ml. R2YE agar without sucrose was used for
infection of S. peucetius with φC31 [60] derivatives. KC515 and
KC515-derived phages were propagated as described by Hopwood et
al. [40]. E. coli strains were grown in LB medium [58] supplemented
with ampicillin (100 mg/ml), apramycin (25 µg/ml) or tetracycline (15
µg/ml) for the selection of plasmids.
Analysis of anthracycline production or bioconversion
Anthracycline metabolites were extracted from liquid medium with
chloroform as described by Otten et al. [42] for S. peucetius and S.
lividans bioconversion experiments, and from solid medium using
chloroform. TLC analysis were performed as in Grimm et al. [61] on
precoated silica gel F60/F254 TLC plates (E. Merck) developed in
the ascending fashion with chloroform:methanol:acetic acid:water
(40:10:0.6:2 v/v) as a mobile phase. HPLC analysis was performed
with a Waters (Milford, MA) Nova-Pak C18 column (3.9 × 150 mm)
as in Madduri et al. [26] with the elution system: 20% B in A (A,
H2O:trifluoroacetic acid (TFA) 0.1%; B, acetonitrile:TFA 0.078%) to
25% B with a linear gradient for 5 min, followed by 25% B to 40% B
with gradient 8 for 10 min, followed by 40% B to 70 % B with a linear
gradient for 10 min, and remaining at 70% B for an additional 6 min.
RHOD used as a reference both for TLC, HPLC and spectral analysis
was provided by William Strohl (Ohio State University). Bioconversion
products were purified by TLC and eluted from the silica gel by
methanol. Molecular weights were determined by mass spectroscopy
using the electrospray ionization mode (ESI–MS) coupled with
tandem MS/MS detection of selected ions.
Determination of anthracycline production in S. peucetius dnm::aphII,
dnmM+ and dnmW strains was done as described by Lomovskaya
et al. [34].
Characterization of RHOD and related products obtained by
bioconversion
From the S. lividans WMH1911 strain grown in APM solid medium in
the presence of RHO (3.5 mg), 210 µg of RHOD were purified by
preparative TLC. HPLC analysis showed a retention time identical to
that of the RHOD standard, and only a single peak with the expected
retention time was observed upon coinjection of the two samples. The
RHOD isolated from the bioconversion was characterized initially by
low resolution ESI–MS and MS/MS analysis. A parent ion was
detected at m/z 558.2 consistent with [RHOD]H+ and the fragmenta-
tion pattern exhibited ions corresponding to [RHOD–H2O]H+ at m/z
540.2, [RHO]H+ at m/z 429.0, [RHO–H2O]H+ at m/z 411.2,
[daunosamine]H+ at m/z 148.0 and [daunosamine–H2O]H+ at m/z
129.8. The standard and isolated samples of RHOD exhibited identical
1H NMR spectra. Products isolated from bioconversion with strains
WMH1913, WMH1914 and WMH1916 carrying the mutant dnmZ,
dnrH or dnmQ genes, respectively, had the same chromatographic and
ESI–MS properties as those of RHOD.
General DNA manipulations
DNA isolation, restriction and ligation were performed according to
standard techniques [58]. Qiaex resin (Qiagen, Chatsworth, CA) was
used routinely to purify DNA fragments from gel slices. Sequencing
reactions using reverse and forward M13 primers were performed with
an ABI Prism BigDye terminator cycle sequencing kit at the facilities
provided by the University of Wisconsin Biotechnology Center. PCR
amplifications were performed in a thermal cycler Perkin–Elmer Cetus
model 480. Amplification of dnrI with its own promoter and dnmJ from
pWHM1898 using the primers COA1-COA2 (Table S2), and dnmT
from pWHM954 (using COA3-COA4, Table S2) were made by dena-
turing the samples at 95°C for 5 min and subjecting them to three sets
of 10 cycles of denaturing at 95°C, 1.5 min, annealing at 50°C first
cycle, 60°C second cycle and 65°C third cycle, for 1 min and elonga-
tion at 72°C for 5 min followed by 1 cycle of 95°C, 1.5 min, 65°C,
1 min and 72°C for 15 min. For amplification of dnmQ and dnmS from
pWHM1899 (using COA5-COA6, Table S2) the same procedure was
used by changing the annealing temperature to 55°C, 60°C and 65°C
in the first, second and third cycles, followed by 1 cycle of 95°C,
1.5 min and 72°C, 10 min. PCR mixtures contained 1× PCR buffer
[10mM Tris-HCl, pH 8.85 (20°C), 25 mM KCl, 5 mM (NH4)2SO4] sup-
plied by Boehringer Mannheim, and MgSO4 1.5mM for the first two
amplifications and 3.5 mM for the last one, which in addition contained
DMSO 5%. Pwo DNA polymerase (2.5 U, Boehringer Mannheim) was
used in these PCRs. Amplification of a partial dnmZ with its own pro-
moter and the dpsY promoter was performed with primers COA7B and
COA7C (Table S2) and pWHM219 DNA by denaturing the samples at
95°C for 5 min, and then 30 cycles of denaturing (95°C, 30 s), anneal-
ing (37°C, 30 s) and elongation (72°C, 3 min) followed by 1 cycle of
denaturing (95°C, 30 s) and elongation (72°C, 5 min). Amplification of
the operon dnmLM+ was performed with primers COA8 and COA9
(Table S2) and pJTR1019 DNA by denaturing the samples at 97°C for
5 min, then 15 cycles of denaturing (97°C, 30 s), annealing (55°C,
45 s) and elongation (72°C, 90 s) followed by 10 cycles of denaturing
(97°C, 30 s), annealing (65°C, 45 s) and elongation (72°C, 90 s) and
10 cycles of denaturing (97°C, 30 s) and elongation (72°C, 2 min). Taq
polymerase (1 U, Promega, Madison, WI) was used in the latter reac-
tions with 1× PCR buffer (50mM KCl, 10 mM Tris–HCl, pH 9.0 (at
25°C), 0.1% Triton X-100), 5mM MgCl2 and DMSO 5%. In all PCR
reactions 20 pmol of each primer was used, each dNTP was present at
200 mM and 1 ng of target DNA was used.
Construction of S. peucetius dnmM::aphII and dnmM+ strains
To prepare the dnmM::aphII mutant, a 1.0 kb SalI fragment containing
the aphII gene from pWHM249 (Table S1) was cloned blunt-ended
between the XcmI and SacII sites in a 1.6 kb EagI–BamHI fragment of
the wild-type dnmM gene in which the frameshift mutation was located.
The fragment containing the dnmM::aphII disrupted copy was cloned
in KC515 as described in Table S1. Protoplasts of S. lividans TK24
were transfected with the phage construct and the recombinant phage
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was isolated from plaques by a convenient spot-test method [62]. The
recombinant phage phWHM461 carrying the dnmM::aphII gene was
characterized phenotypically by its neomycin and viomycin resistance
because the thiostrepton resistance gene in KC515 was replaced by
the cloned fragment. The presence of the cloned DNA was confirmed
by restriction endonuclease digestion analysis. S. peucetius 29050
was infected with phWHM461 (Table S1) and clones resistant to
neomycin and viomycin as well as clones resistant only to neomycin
were obtained. Clones resistant only to neomycin were expected to
have undergone dnmM gene replacement through double crossover
recombination. PCR analysis of the genomic DNA from six clones was
performed to confirm that homologous recombination had taken place
between the cloned fragment and genomic DNA in the dnmM region.
One of the primers for this PCR reaction was located inside the aphII
gene and another outside of the cloned fragment, 1.2 kb away from the
first primer. The WMH1800 strain was chosen as a representative
dnmM::aphII mutant.
The frameshift in the wild-type dnmM gene was repaired using PCR
mutagenesis and the structure of the dnmM+ gene in the resulting
plasmid, pJTR1019, was verified by DNA sequencing. A few other errors
in the reported DNA sequence of the last few nucleotides of dnmL and
the dnmM gene were corrected during this work. The recombinant
phage containing the dnmM+ gene, cloned as a 2.0 kb AvrII–BamHI
fragment from pJTR1019, was constructed as described in Table S1.
The phage was isolated after transfection of S. lividans TK24 proto-
plasts. The phWHM463 containing the dnmM+ gene was characterized
using a PCR reaction with unique primers located within the cloned frag-
ment and by thiostrepton resistance because the viomycin resistance
gene in KC515 was replaced by the cloned fragment.
The S. peucetius dnmM+ strain was obtained by replacing the
dnmM::aphII copy in WMH1800 with the dnmM+ fragment. Strain
WMH1800 was infected with phWHM463 to obtain clones resistant
to neomycin and thiostrepton. From progeny of these clones, two
neomycin- and thiostrepton-sensitive clones, WMH1801 and WMH1802,
were isolated and expected to be produced as a result of double
crossover recombination between chromosomal DNA and cloned
dnmM+ fragment. PCR analysis with suitable primers revealed the pres-
ence of a unique 1.4 kb amplified band in the DNAs from WHM1801
and WMH1802, consistent with replacement of dnmM::aphII by the
dnmM+ gene.
Construction of daunosamine gene clusters
A region of 2,176 bp containing dnrI and dnmJ under the control of dnrI
promoter (dnrIp) was amplified from pWHM1898 and the resultant
product cloned in pUC19 as an EcoRI–HindIII fragment. An internal
2,064 bp BamHI–BglII fragment from pWHM1898 was used to replace
the most of the PCR product, resulting in pWHM1900 (Figure S1a). In
this and all other constructs, any DNA introduced by PCR and not so
replaced was verified by sequence analysis. Clone pWHM1900 was
digested with BglII and EcoRI and two fragments were cloned in it at
these sites; a 1,672 bp BglII–BamHI fragment from pWHM1898 (con-
taining part of the dnmJ, dnmV and dnmU genes) and a PCR amplifica-
tion product (primers COA7B and COA7C, Table S2) from pWHM219
[25] containing a partial dnmZ gene and the bifunctional promoter for
dnmZ and dpsY as a BamHI–EcoRI fragment. In the resulting
pWHM1903 (Figure S1a), an internal 900 bp SrfI–MluI fragment was
replaced by the original sequence from pWHM219 to give pWHM1904
(Figure S1a). Construct pWHM1901 (Figure S1b) was obtained by
amplifying a 1,590 bp fragment from pWHM954 [22] then cloning this
DNA in pUC19 as a EcoRI–HindIII fragment, which was digested with
RsrII–Bpu1102I to remove a 1,460 bp fragment and replace it by the
original sequence from pWHM954. The dnmQS genes were PCR
amplified from pWHM1989 as a 2,720 bp fragment that was cloned in
pUC19 as an EcoRI–HindIII fragment. Most of this DNA was replaced
by a 3,090 bp BssHII–EcoRI fragment from pWHM1989 to give
pWHM1902 (Figure S1b). Both pWHM1901 and pWHM1902 were
digested with EcoRI and EcoRV, then the 3,208 bp fragment resulting
from pWHM1902 was cloned in pWHM1901 to obtain pWHM1905
(Figure S1b). Finally, pWHM1904 and pWHM1905 were digested with
HindIII and AflII or AflII and EcoRI, respectively, and both fragments
were cloned in pWHM3 to give pWHM1906 (Figure 2b).
Two additional plasmids were made to replace dnmT in pWHM1905 by
the whole operon containing dnmW, dnmT and dnrH. The source of
this operon was pWHM377 containing a 4.0 kb SstI–BclI fragment
from pWHM555 [34]. For the first construct, a 3.9 kb EcoRI–AflII frag-
ment was cloned blunt-ended into pWHM1901 previously digested
with Bpu1102I and the overhanging ends filled in by treatment with the
Klenow fragment then digested with NaeI to remove dnmT. The result-
ing plasmid, pWHM1901a, was digested with EcoRV and HindIII and
the resulting fragment was cloned into pWHM1902 to give
pWHM1907 in which dnmW, dnmT, dnrH, dnmQ and dnmS are under
the control of dnmW promoter (Figure S1c). Finally, pWHM1904 and
pWHM1907 were digested with HindIII and AflII or AflII and EcoRI,
respectively, and both of these fragments were cloned in pWHM3 to
obtain pWHM1909 (Figure 2b). The second construction was made by
cloning a 3.9 kb EcoRI–AflII fragment into pWHM1901 previously
digested with these same restriction enzymes to remove dnmT. The
resulting plasmid, pWHM1901b, was digested with EcoRI, blunt-ended
by treatment with the Klenow fragment then digested with HindIII and
the resulting fragment was cloned into EcoRV- and HindIII-digested
pWHM1902 to give pWHM1908 in which dnmW, dnmT and dnrH are
under the control of the dnmW promoter and dnmQ and dnmS under
control of the dpsG promoter (Figure 2b). Finally, pWHM1904 and
pWHM1908 were digested with HindIII and AflII or AflII and EcoRI,
respectively, and both of the resulting fragments were cloned in
pWHM3 to obtain pWHM1910 (Figure 2b). In both pWHM1909 and
pWHM1910 321 bp from the dnrE coding region downstream of dnrH
were included in the cloning process (dnrE encodes a ketoreductase
required for RHO biosynthesis [22]).
Construction of daunorubicin resistance plasmids carrying the
dnmLM or mtmDE genes
Genes for the two enzymes common to all the deoxysugar pathways,
TDP-glucose-1-phosphate thymidylyltransferase and TDP-glucose-4,6-
dehydratase, and the drrAB daunorubicin resistance genes were
cloned in pWHM601 as follows. The drrAB genes were obtained from
pWHM611 [31] as a 2.5 kb NcoI–AflIII fragment and cloned after blunt
ending in pUC19 digested with SmaI. The correct orientation of drrAB
was selected and designated pWHM1911, then this plasmid was
digested with StyI, blunt ended, and digested with HindIII, followed by
cloning together with a 2.7 kb StuI–HindIII fragment from plasmid
pFLADE [32] containing the mtmDE genes. From the resulting con-
struction an EcoRI–HindIII fragment was subcloned in pWHM601 to
give pWHM1912 (Figure 2a). In this plasmid the mtmD and mtmE
genes are under the control of the dnrF promoter [31]. A second
plasmid containing dnmL and dnmM+ was prepared by PCR amplifica-
tion of a 2.3 kb fragment from pJTR1019 using primers COA8 and
COA9 (Table S2).The EcoRI–HindIII digested PCR product was
cloned in pUC19 and the resultant construction was digested with
ApaI and BstEII. The 400 bp ApaI–BlpI and 1.9 kb BlpI–BstEII frag-
ments from pJTR1019 were used to replace most of the PCR DNA in
the linearized DNA to give pWHM1913. From pWHM1913 a
NcoI–HindIII fragment was cloned in NcoI- and HindIII- digested
pWHM1911 to obtain pWHM1914. From pWHM1914 the EcoRI–
HindIII fragment was cloned in pWHM601 to give pWHM1915
(Figure 2a, Table S1).
Different strains of S. lividans 1326 were obtained by transformation
with plasmids containing the dnm or mtm genes and the drrAB resis-
tance genes (Table S1). All strains carrying pWHM1912 tested were
resistant to 10 µg/ml DNR (data not shown).
Construction of plasmids with mutant dnm genes
Modified versions of pWHM1910 with deletions in some of the genes
involved in L-daunosamine biosynthesis were generated as follows.
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pWHM1903 that contains a truncated version of dnmZ was used to
make pWHM1916 by cloning an HindIII–AflII fragment from pWHM1903
and an AflII–EcoRI fragment from pWHM1908 together in pWHM3. The
∆dnmZ gene in pWHM1916 encodes a 60 amino acid protein having
only the first 51 amino acids of the deduced DnmZ protein. A plasmid
with an in-frame deletion in dnrH was constructed by BamHI–SgrAI
digestion of pWHM1901b, blunt-ending the resulting DNA followed by
religation into a plasmid, then removing a 918 bp fragment to give
pWHM1917 from which an EcoRI (blunt ended)–HindIII fragment was
cloned in EcoRV- and HindIII-digested pWHM1902 to give
pWHM1918. From this plasmid an AflII–EcoRI fragment was cloned in
pWHM3 together with a HindIII–AflII fragment from pWHM1904 to give
pWHM1919. In the latter plasmid the ∆dnrH gene encodes a protein of
137 amino acids without the 306 amino acids between residues 135
and 440 of the DnrH protein. The fragment pWHM1910 with an in-
frame deletion in the dnmW gene was constructed by digestion of
pWHM1908 with SphI (followed by blunt ending) and PshAI, which
removes a 393 bp fragment, and religation to give pWHM1920. An
AflII–EcoRI fragment from pWHM1920 was cloned together with a
HindIII–AflII fragment from pWHM1904 in pWHM3 to give pWHM1921.
In the latter plasmid, the ∆dnmW gene encodes a 63 amino acid protein
without the 131 amino acids between residue 5 and 135 of the DpsH
protein. A frameshift mutation in the dnmQ gene was constructed by SfrI
digestion of pWHM1905 and religation, followed by removal of a 575
bp fragment to give pWHM1922. An EcoRV–HindIII fragment contain-
ing dnmT was removed from this plasmid and the remaining DNA was
cloned with an EcoRI (blunt ended)–HindIII fragment from pWHM1901b
to give pWHM1923. From this plasmid an AflII–EcoRI fragment was
cloned in pWHM3 together with a HindIII–AflII fragment from
pWHM1904 to give pWHM1924. The mutant dnmQ gene in the latter
plasmid encodes a 251 amino acid protein without the first 220 amino
acids of the DnmQ protein.
All of the above plasmids with dnm mutations were introduced by
tranformation into S. lividans 1326 together with pWHM1912 to gen-
erate strains WMH1913, WMH1914, WMH1915 and WMH1916
(Table S1).
Supplementary material
Supplementary material with a table of the strains and plasmids used, a
table of the oligodeoxynucleotide primers used and a figure showing
the structure of the clones used to generate the daunosamine gene
clusters is available at http://current-biology.com/supmat/supmatin.htm.
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